Agios Pharmaceuticals | Le Bénéfice D'Exploitation



Operating Profit Changement Date
AbbVie USD -1490000000 5.32B 2024-12
Agios Pharmaceuticals USD -125037000 1.11B 2024-12
Alnylam Pharmaceuticals USD -105159000 28.25M 2024-12
Amgen USD 2.31B 182M 2024-12
Arrowhead Research USD -161412000 791K 2024-12
Astellas Pharma JPY -116191000000 159.24B 2024-12
AstraZeneca USD 2.04B 731M 2024-12
Bayer EUR 3.53B 7.35B 2024-12
Biogen USD 441.4M 24.4M 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Daiichi Sankyo JPY 61.41B 32.51B 2024-12
Eli Lilly USD 5.15B 3.62B 2024-12
Exelixis USD 163.21M 27.13M 2025-01
Gilead Sciences USD 2.45B 1.56B 2024-12
GlaxoSmithKline GBP 696M 507M 2024-12
Incyte USD 301.51M 155.43M 2024-12
Ionis Pharmaceuticals USD -110823000 37.83M 2024-12
Merck USD 4.3B 369M 2024-12
Moderna USD -1246000000 1.18B 2024-12
Novartis USD 2.28B 1.34B 2024-12
Novartis USD 3.4B 193M 2024-12
Pfizer USD -409000000 5.57B 2024-12
Regeneron Pharmaceuticals USD 990.2M 189.3M 2024-12
Roche Holding CHF 4.39B 1.04B 2024-12
Sarepta Therapeutics USD 161.68M 139.48M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



Agios Pharmaceuticals Le Bénéfice D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.